“The 100th anniversary of Saccharomyces boulardii CNCM I-745 is an important milestone, but there is more work to be done. Educating people on the benefits of a balanced gut microbiota and making it accessible for all is what drives us to continue to explore this powerful probiotic yeast strain.”
BEDMINSTER, N.J. (PRWEB)
June 22, 2023
Saccharomyces boulardii CNCM I-745, the first yeast-based probiotic strain discovered in 1923 by French microbiologist Henri Boulard and first commercialized by Biocodex Inc., maker of the Florastor®, the only probiotic that contains this exclusive strain, represents a century of probiotic pioneering, scientific advancements, and positive impact on human health. As this unique strain celebrates 100 years, the company has its eyes set on the future of the science of the microbiome and new discoveries to support common occasional health issues.
“While many people may think of probiotics as being ‘all the same’ or ‘one size fits all’, probiotics are actually unique, living microorganisms that are strain-specific in their actions and each strain works in different areas of the intestines.” says Karen Taylor, RN, BSN, Director of Medical Education and Medical Science Liaison at Biocodex. “The strain, Saccharomyces boulardii CNCM I-745 has a rich, scientific history. This specific yeast strain has helped more than 460 million people around the globe just since the 1980s, has been studied in more than 130 clinical trials, and Biocodex has been a pioneer of probiotics, paving the way to help people become educated about microbiota care.”
Saccharomyces boulardii CNCM I-745, a unique yeast strain, was first discovered by Boulard during his travels in Southeast Asia. “He observed locals drinking a mixture made from the skin of two tropical fruits, lychees and mangosteens, to help relieve stomach problems, including occasional diarrhea,” explains Taylor. “This drink was found to have a single, specific yeast strain that he called Saccharomyces boulardii.”
Since it was commercialized in 1953, Saccharomyces boulardii CNCM I-745 has been used to help treat, prevent, and recover from occasional diarrhea and creates a favorable growth environment for the beneficial gut microbiota after an imbalance created by diarrhea.
“The 100th anniversary of Saccharomyces boulardii CNCM I-745 is an important milestone, but there is more work to be done,” says Julien Dureisseix, General Manager of Biocodex, Inc. “Educating people around the globe on the health benefits of a balanced gut microbiota and making it accessible for all is what drives us to continue to explore the full potential of this powerful probiotic yeast strain.”
About Biocodex, Inc.
As an international pharmaceutical company, it is the mission of Biocodex to improve the health and well-being of people worldwide through our three main areas of expertise: microbiota care, women’s health and orphan diseases. As a pioneer in the use of probiotics for therapeutic purposes, Biocodex aims to become the leader in microbiota care. In addition to offering innovative products and solutions, Biocodex is dedicated to advancing scientific research, and using our expert knowledge for the benefit of all. They strive to meet this ongoing challenge by taking a responsible and sustainable approach.
Share article on social media or email: